Findings

What do systematic reviews say?

178 questions · 181 findings · 13 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 33 · 18.2%GRADE not reported 13 · 7.2%Very low 46 · 25.4%Low 37 · 20.4%Moderate 42 · 23.2%High 10 · 5.5%

Atypical antipsychotics vs placebo

Somnolence

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
High

Atypical antipsychotics vs placebo

Death ‐ 5032 persons in 17 RCTs of 3 to 12 weeks ___________________________________________

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Atypical antipsychotics vs placebo

Specific behaviour ‐ agitation

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Atypical antipsychotics vs placebo

Response for agitation ‐ as defined by authors of RCTs ‐ 1303 persons in 4 RCTs of 3 to 12 weeks

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Atypical vs atypical antipsychotics (only short term)

No improvement (clozapine vs olanzapine) · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39 participants
High

Atypical vs atypical antipsychotics (only short term)

Drug‐induced diabetes (clozapine vs olanzapine) · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 28 participants
Moderate

Atypical vs atypical antipsychotics (only short term)

Elevated prolactin (risperidone vs quetiapine) · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Moderate

Atypical vs atypical antipsychotics (only short term)

Weight gain · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 76 participants
High

Atypical vs atypical antipsychotics (only short term)

Leaving the study early because of weight gain (risperidone vs olanzapine) · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 19 participants
Low

Atypical vs atypical antipsychotics (only short term)

No improvement (risperidone vs olanzapine) · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 111 participants
Moderate

Atypical vs typical antipsychotics (only short term)

Worse or no improvement · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 21 participants
Low

Atypical vs typical antipsychotics (only short term)

Adverse effects ‐ anticholinergic effects · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Moderate

Atypical vs typical antipsychotics (only short term)

Drop in the absolute neutrophil count below 1500 per mm3 · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 21 participants
Very low

Atypical vs typical antipsychotics (only short term)

Adverse effects: Leaving the study early · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 21 participants
Moderate

Intervention not reported

Atypical antipsychotics vs placebo · critically ill adult with confirmed or at high risk of delirium

1 finding from 1 review

Pharmacological interventions for the treatment of delirium in critically ill adults 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 476 participants
Moderate

Atypical (standard‐dose) vs atypical (low‐dose) antipsychotics (only short term)

No response · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 255 participants
High

Atypical (standard‐dose) vs atypical (low‐dose) antipsychotics (only short term)

Symptomatic hyperprolactinaemia · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 257 participants
High

Atypical (standard‐dose) vs atypical (low‐dose) antipsychotics (only short term)

Use of antiparkinsonian medications · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 257 participants
High

Atypical (standard‐dose) vs atypical (low‐dose) antipsychotics (only short term)

Weight gain · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 257 participants
High

Typical vs atypical antipsychotics

All‐cause mortality · delirious patients

Typical showed no clear difference in mortality compared with atypical antipsychotics (moderate certainty).

1 finding from 1 review

Antipsychotics for treatment of delirium in hospitalised non‐ICU patients 2018 · Cochrane Headline outcomes only
RR 1.71 [0.82, 3.53]
4 studies · 342 participants
Moderate